Mediators of Inflammation

Mediators of Inflammation / 2020 / Article
Special Issue

Role of Inflammasomes in Inflammatory and Infectious Diseases

View this Special Issue

Research Article | Open Access

Volume 2020 |Article ID 2545682 |

Maria Luiza Thorstenberg, Monique Daiane Andrade Martins, Vanessa Figliuolo, Claudia Lucia Martins Silva, Luiz Eduardo Baggio Savio, Robson Coutinho-Silva, "P2Y2 Receptor Induces L. amazonensis Infection Control in a Mechanism Dependent on Caspase-1 Activation and IL-1β Secretion", Mediators of Inflammation, vol. 2020, Article ID 2545682, 11 pages, 2020.

P2Y2 Receptor Induces L. amazonensis Infection Control in a Mechanism Dependent on Caspase-1 Activation and IL-1β Secretion

Academic Editor: Tae Jin lee
Received26 Jun 2020
Accepted07 Sep 2020
Published01 Oct 2020


Leishmaniasis is a neglected tropical disease caused by an intracellular parasite of the genus Leishmania. Damage-associated molecular patterns (DAMPs) such as UTP and ATP are released from infected cells and, once in the extracellular medium, activate P2 purinergic receptors. P2Y2 and P2X7 receptors cooperate to control Leishmania amazonensis infection. NLRP3 inflammasome activation and IL-1β release resulting from P2X7 activation are important for outcomes of L. amazonensis infection. The cytokine IL-1β is required for the control of intracellular parasites. In the present study, we investigated the involvement of the P2Y2 receptor in the activation of NLRP3 inflammasome elements (caspase-1 and 11) and IL-1β secretion during L. amazonensis infection in peritoneal macrophages as well as in a murine model of cutaneous leishmaniasis. We found that 2-thio-UTP (a selective P2Y2 agonist) reduced parasite load in L. amazonensis-infected murine macrophages and in the footpads and lymph nodes of infected mice. The antiparasitic effects triggered by P2Y2 activation were not observed when cells were pretreated with a caspase-1 inhibitor (Z-YVAD-FMK) or in macrophages from caspase-1/11 knockout mice (CASP-1,11−/−). We also found that UTP treatment induced IL-1β secretion in wild-type (WT) infected macrophages but not in cells from CASP-1,11−/− mice, suggesting that caspase-1 activation by UTP triggers IL-1β secretion in L. amazonensis-infected macrophages. Infected cells pretreated with IL-1R antagonist did not show reduced parasitic load after UTP and ATP treatment. Our in vivo experiments also showed that intralesional UTP treatment reduced both parasite load (in the footpads and popliteal lymph nodes) and lesion size in wild-type (WT) and CASP-11−/− but not in CASP-1,11−/− mice. Taken together, our findings suggest that P2Y2R activation induces CASP-1 activation and IL-1β secretion during L. amazonensis infection. IL-1β/IL-1R signaling is crucial for P2Y2R-mediated protective immune response in an experimental model of cutaneous leishmaniasis.

1. Introduction

Leishmaniasis is a vector-borne disease caused by flagellated protozoans of the genus Leishmania. This disease represents a spectrum of neglected tropical diseases that are endemic in 98 countries worldwide [1]. The clinical manifestations range from cutaneous or mucocutaneous lesions to lethal visceral pathology. Cutaneous leishmaniasis, whose symptoms range from local ulcers to mucosal tissue destruction, can be caused by L. amazonensis, L. major, L. braziliensis, and L. guaynensis [2].

In humans, Leishmania promastigotes are injected into the dermis (i.e., through the bite of an infected sandfly) and establish infection in phagocytic cells [3]. The recognition of pathogen-associated molecular patterns (PAMPs) by phagocytes leads to the release of damage-associated molecular patterns (DAMPs) such as the extracellular nucleotides ATP (eATP) and UTP (eUTP) that are involved in the killing of intracellular pathogens through the activation of P2 receptors ([4, 5]. P2 purinergic/pyrimidinergic receptors can be subdivided into metabotropic G-protein-coupled P2Y (P2Y1,2,4,6,11–14) and ionotropic P2X receptors (P2X1–7) [6]. The following agonists activate P2 receptors: P2X and P2Y11–ATP; P2Y2,4–ATP and –UTP; P2Y1, P2Y12, and P2Y13–ADP; P2Y6–UDP; and P2Y14–UDP–glucose [7]. P2Y receptors (P2YR) can be constitutively expressed or regulated under pathological conditions [8]. Metabotropic G-coupled-proteins such as calcium-sensing receptor and P2YR were reported to be implicated in NLRP3 inflammasome activation in inflammatory models [913].

Evidence supports the involvement of the noncanonical NLRP3 inflammasome assembly in the elimination of L. amazonensis infection by P2X7R triggering, acting as an important platform to improve host leishmanicidal mechanisms. Nevertheless, the mechanisms involved in the activation of this inflammasome in leishmaniasis remain elusive [14, 15]. ATP/P2X7R signaling during L. amazonensis infection has been partially elucidated during the last decade; it is assumed to be the most potent canonical activator of the NLRP3 inflammasome [16] and more recently in noncanonical activation of NLRP3 inflammasome assembly [14, 17, 18]. We previously demonstrated that the antiparasite immune response attributed to the P2YR agonist UTP involves paracrine activation of the P2X7 receptor (P2X7R) and PANX-1 channels in macrophages from mice infected with L. amazonensis [19]; UTP induces production and release of reactive oxygen species (ROS), nitrite oxide (NO) [20, 21], and leukotriene B4 (LTB4) [19] that is assumed to be crucial for parasite death. In addition to these inflammatory mediators, IL-1β mediates the control of intracellular parasite infections [4] [22]. In the present study, we investigated caspase-1/IL-1β axis activation in the protective immune response induced by P2Y2 receptor activation in an experimental model of cutaneous leishmaniasis.

2. Materials and Methods

2.1. Chemicals

UTP (uridine triphosphate), ATP (adenosine triphosphate), Dulbecco’s modified Eagle’s medium (DMEM), and 199 medium were purchased from Sigma-Aldrich (St. Louis, MO, USA); 2-thio-UTP and FMK-Z-YVAD were from Tocris (Bristol, UK).

2.2. Mice

The experiments, maintenance, and care of mice were carried out according to the guidelines of the Brazilian College of Animal Experimentation (COBEA). We used wild-type BALB/c and C57BL/6 (Jackson Laboratory, USA), as well as CASP-1,11 and CASP-11 knockout mice (CASP-1,11-/- and CASP-11-/- against the C57BL/6 background) (Genentech Laboratory, South San Francisco, CA, USA). CASP-1,11-/- and CASP-11-/- mice were maintained at the Laboratory of Transgenic Animals of the Federal University of Rio de Janeiro (UFRJ, RJ, Brazil). The mice were housed in a temperature-controlled room (22°C) with a light/dark cycle (12 h). Food and water were provided ad libitum. The animal experimentation protocols used in this study were approved by the Ethics Committee on the Use of Animals (CEUA) from the IBCCF, UFRJ, document no. 077/15.

2.3. Parasite Culture

We used L. amazonensis (MHOM/BR/Josefa) strain in both in vitro and in vivo experiments. Amastigotes isolated from mouse lesions (from BALB/c mice) were allowed to transform into axenic promastigote forms by growth at 24°C, for 7 days, in 199 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco BRL, 2% male human urine, 1% L-glutamine and 0.25% hemin). Promastigotes in the late stationary phase of growth until the tenth passage were used to preserve parasite virulence.

2.4. Cell Culture and Infection

Resident macrophages were harvested from the peritoneal cavity by washes with cold phosphate buffer saline (PBS). Cells were directly seeded on culture plates (in DMEM-supplemented medium, at 37°C, with 5% CO2) for 1 h and washed gently with PBS (twice) to remove nonadherent cells. The cells were cultured for 24 h in DMEM supplemented (10% FBS and 100 units penicillin/streptomycin) at 37°C (and 5% CO2) and infected for 4 h or 1 h with L. amazonensis promastigotes (MOI ratio 10 : 1, Leishmania: macrophage) at 37°C. The noninternalized parasites were removed by extensive washing with sterile PBS. Then, infected cells were maintained in an incubator at 37°C and 5% CO2 until the moment of stimulation.

2.5. In Vitro Stimulus and Inhibitor Treatments

Infected macrophages (48 h after infection) were treated with 10 μM Z-YVAD-FMK, 2 μM Z-LEVD-FMK, or IL-1Ra (100 ng/mL) for 30 minutes before stimulation with UTP (100 μM) or ATP (50, 100, or 500 μM) for an additional 30 minutes at 37°C and 5% CO2. Then, cell monolayers were washed with PBS and maintained in DMEM supplemented (10% FBS and 100 units penicillin/streptomycin) at 37°C (and 5% CO2) for 24 h, when infection index and cytokine production were measured.

2.6. Macrophage Infection Index

Intracellular parasite loads were analyzed as previously described [19]. Briefly, cells were infected and treated with nucleotides and were fixed onto slides, stained using a panoptic stain (Laborclin®, PR, Brazil), and counted using a Primo Star light microscope (Zeiss, Germany), with a 40x objective (100x for representative pictures). Images were acquired using a Bx51 camera (Olympus, Tokyo Japan) operated using the Cell^F software. We calculated the “infection index,” representing the overall infection load, based on the count of about 100 cells in a total of five fields to obtain the number of infected macrophages and the average number of parasites per macrophage. Individual amastigotes were clearly visible in the cytoplasm of infected macrophages. The results were expressed as the .

2.7. Murine Model of Infection and In Vivo Treatments

Female BALB/c mice, wild-type (WT), CASP-1,11-/-, and CASP-11-/- C57BL/6 (8–12 weeks old) were infected in the dermis of the footpad by intradermal injection of 106L. amazonensis promastigotes in PBS. Intralesional treatment with 20 μL of 10 μM 2-thio-UTP, 1 mM UTP (), or vehicle (for 3 weeks, twice a week) started 7 days postinfection (d.p.i.). Lesion growth was calculated by evaluation of the “swelling” (thickness of the infected footpad − thickness of the uninfected footpad from the same mouse), using a traditional caliper (Mitutoyo®). Forty-eight hours after the final injection (26 d.p.i.), the animals were euthanized, and the infected footpad and popliteal lymph nodes were removed and dissociated (in M199-supplemented culture medium) for parasitic load determination.

2.8. Parasite Number in Mouse Tissues

The parasite load of L. amazonensis in infected tissues was determined using a limiting dilution assay, as previously described [19, 23]. Mice were euthanized in a CO2 chamber, followed by cervical dislocation. The footpads and lymph nodes were collected and weighed, and cells from the whole footpad and draining lymph nodes were dissociated using a cell strainer 40 μm (BD®) in PBS. Large pieces of tissue debris were removed by centrifugation at 150 g; cells were separated by centrifugation at 2,000 g for 10 min and resuspended in supplemented M199. Samples were cultured in 96-well flat-bottom microtiter plates (BD®, USA) at 26–28°C. After a minimum of 7 days, wells were examined using phase-contrast microscopy in an inverted microscope (NIKON TMS, JP) and scored as “positive” or “negative” for the presence of parasites. Wells were scored “positive” when at least one parasite was observed per well.

2.9. Cytokine Levels

Measuring IL-1β released in cell supernatants, peritoneal macrophages from WT, and CASP-1,11-/- mice were plated in 96-well plates () and infected with promastigotes of L. amazonensis (MOI 10 : 1) as described in Section 2.4. Then, cells were treated with 100 μM UTP or 3 mM ATP for 30 min. Cells were washed after 30 min and maintained at 37°C for an additional 4 h, and the supernatants were collected for further analyses. Enzyme-linked immunosorbent assays (ELISA) were performed using commercial kits, as instructed by the manufacturer (R&D Systems, Minneapolis, MN, USA). We also measured cytokine production in footpads from WT, CASP-1,11-/-, and CASP-11-/- mice. Briefly, the infected footpads were collected and processed as described above. IL-1β and IL-1α levels were measured using ELISA with commercial kits, as instructed by the manufacturer (R&D Systems, Minneapolis, MN, USA). Protein concentrations were determined using the bicinchoninic acid method (Thermo Fisher, BCA protein assay kit, Rockford, IL, USA), and cytokine levels in tissue were corrected for by the total amount of protein.

2.10. Statistical Analysis

Statistical analyses were performed using the Student’s -test to compare two groups. For more than two groups, data were analyzed using the one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison post hoc test, using the Prism 5.0 software (GraphPad Software, La Jolla, CA, USA). Differences between experimental groups were considered statistically significant when .

3. Results

3.1. P2Y2R Contributes to L. amazonensis Infection Control

We recently reported that UTP-intralesional treatment elicited a Th1 immune response in an experimental model of cutaneous leishmaniasis [21], suggesting the involvement of P2Y2R. Here, we evaluated whether the intralesional treatment with a selective P2Y2R agonist (2-thio-UTP) would promote L. amazonensis control in BALB/c mice. As shown in Figure 1(a), tissues were harvested for analysis at 26 d.p.i. We found that 2-thio-UTP treatment reduced the parasitic load in the footpads (Figure 1(b)) and draining lymph nodes (Figure 1(c)), as well as the number of leukocytes in the draining lymph nodes of infected mice (Figure 1(d)) when compared to those of control mice. We also investigated the antiparasitic effect attributed to 2-thio-UTP (range 0.025–1 μM) and UTP (range 1–100 μM) in infected macrophages. We found that all concentrations of UTP significantly reduced the infection index in both BALB/c (Figure 1(f)) and C57BL/6 WT macrophages (Figure 1(h)). Antiparasitic effects of 2-thio-UTP treatment were observed at concentrations ranging from 0.05 to 1 μM in both BALB/c (Figure 1(g)) and C57BL/6 WT macrophages (Figure 1(i)). These results suggest that P2Y2R activation contributes to the control of L. amazonensis infection.

3.2. Caspase-1 Is Required to P2Y2R-Mediated L. amazonensis Control in Macrophages

Previously, we showed that antiparasite effects attributed by UTP and ATP involve P2X7R and PANX-1 channels in infected macrophages [19]. We also reported that antiparasitic immune responses triggered by the ATP/P2X7R/PANX-1 axis require NLRP3 inflammasome activation in macrophages infected with L. amazonensis [14]. Here, we determined whether CASP-1 activation (an essential component of the NLRP3 inflammasome) participates in infection control mediated by eUTP. We found that the antileishmanial effects of UTP were absent in infected macrophages from mice genetically deficient for CASP-1,11 enzymes (CASP-1,11−/− mice) (Figures 2(b)2(f)). When we blocked CASP-1 with Z-YVAD-FMK (CASP-1 inhibitor), the antiparasitic effects attributed to UTP treatment were abrogated (Figures 3(b)3(f)). By contrast, the antiparasitic effects of UTP were significant in macrophages from CASP-11−/− mice and in WT macrophages treated with Z-LEVD-FMK (CASP-11 inhibitor) (Supplementary Figure 1). These findings suggest that the activity of CASP-1 but not CASP-11 is relevant to L. amazonensis control mediated by the P2Y2 receptor.

3.3. P2Y2R Stimulation Promotes IL-1β Secretion from L. amazonensis-Infected Macrophages

IL-1β is an important proinflammatory cytokine produced in response to several pathogens, and its secretion is induced by inflammasome activation in a P2X7-dependent manner during L. amazonensis infection [24]. Therefore, we determined whether activation of the inflammasome via UTP/P2Y2R would result in the secretion of IL-1β by L. amazonensis-infected cells. We found that UTP treatment induced IL-1β secretion in WT-infected macrophages but not in macrophages from CASP-1/11−/− mice (Figure 4(a)), suggesting that activation of the canonical NLRP3 inflammasome by eUTP triggers IL-1β secretion in L. amazonensis-infected macrophages in a caspase-1-dependent fashion. Treatment with UTP or ATP did not reduce the parasitic load in infected macrophages pretreated with IL-1R antagonist (Figures 4(b)4(i)), suggesting that IL-1R signaling is essential to L. amazonensis control mediated by P2X and P2Y receptors.

3.4. Treatment with UTP Promotes the Control of In Vivo L. amazonensis Infection through Caspase-1 Activation and IL-1β Production

To confirm the importance of the CASP-1 activation by UTP/P2Y2 activation, we evaluated the requirement of CASP-1 in the protection elicited by UTP treatment during L. amazonensis infection in vivo. We injected UTP at intervals of 3–4 days, from 7 days postinfection in the footpads of WT, CASP-1,11−/−, and CASP-11−/− mice infected with 106 promastigotes of L. amazonensis. Mice were euthanized 26 days postinfection, and lesion development (swelling) was measured during the development of leishmaniasis (Figure 5(a)). As depicted in Figure 5(b), WT mice treated with UTP showed significantly smaller lesion sizes and lower parasite loads (the final one both in the footpads and lymph nodes) than in control mice (Figures 5(b), 5(e), and 5(f)). However, these protective effects were absent in CASP-1,11−/− mice, where UTP treatment did not reduce either lesion size or parasite load (Figures 5(c), 5(e), and 5(f)). UTP treatment in CASP-11−/−-infected mice did not significantly decrease lesion size but rather induced a significant reduction in parasite load (Figures 5(d), 5(e), and 5(f)). Of note, both knockouts showed increased parasite loads when compared to infected WT mice (Figures 5(e) and 5(f)), as previously reported [15].

We also evaluated whether CASP-1 and CASP-11 were relevant to the production of IL-1β and IL-1α in mice treated with UTP. The footpads from infected WT and CASP-11−/− mice treated with UTP showed higher levels of IL-1β, as compared to the control footpads (Figure 5(g)). However, no increase in IL-1β was found in the footpads of UTP-treated CASP-1,11−/− mice (Figure 5(g)), suggesting that CASP-1 is involved in UTP-induced IL-1β production. Levels of IL-1α did not differ in the footpads from WT, CASP-1,11−/−, and CASP-11−/− mice after UTP treatment (Figure 5(h)).

4. Discussion

Cutaneous leishmaniasis affects millions of people worldwide. Nevertheless, the host defense mechanisms that are modulated to control parasite replication and treat the disease are not thoroughly characterized, and several aspects of the disease remain poorly understood [25]. We previously reported the involvement of purinergic receptors, including P2Y2R and P2X7R, in the control of L. amazonensis infection in vitro and in vivo [4, 19]. These receptors induce the activation of several microbicidal mechanisms in host cells during infection (i.e., NO, ROS, LTB4 production) [20, 21, 26, 27]. Here, we identified a protective mechanism triggered by P2Y2R, using incubation with either a specific agonist for P2Y2R, 2-thio UTP, or low concentrations of UTP (100 μM) or ATP (50 μM) during in vitro infection with L. amazonensis. Parasite elimination upon P2Y2R activation in vitro and in vivo depends on caspase-1 activation and IL-1R signaling.

The role of P2X7R in the IL-1β maturation via NLRP3 inflammasome assembly in both infectious and inflammatory disorders is currently accepted [16, 28, 29]. Jin et al. [10] also proposed a P2Y2R-mediated inflammasome activation pathway [10]. Interestingly, inflammasome assembly and signaling are closely associated with the physiopathology of leishmaniasis [3032]. We and others have shown that the NLRP3 inflammasome is protective and contributes to restricting L. amazonensis parasite replication in macrophages as well as in vivo [30, 33, 34]. The canonical NLRP3 inflammasome promotes IL-1β and IL-18 activation through the engagement of NLRP3, ASC, and caspase-1 activation. In addition to these components, the noncanonical NLRP3 inflammasome requires a caspase-11 expression for proper caspase-1 activation [35].

Despite the apparent importance of the inflammasome for disease outcomes, the mechanisms by which NLRP3 inflammasome is activated during Leishmania infection remain poorly understood. ROS production via dectin-1 and P2X7R activation appears to be involved in NLRP3 inflammasome activation [14, 34]. The mechanisms of NLRP3 inflammasome activation required for IL-1β generation during infection by Leishmania have been recently elucidated. IL-1β from a noncanonical NLRP3 source was implicated in the elimination of pathogens [36, 37] including L. amazonensis [14]. In support of this finding, caspase-11 was shown to be activated in response to the cytosolic delivery of Leishmania LPG in macrophages [30]. Previous in vitro studies from our group reported that ATP/P2X7 axis was critical for L. amazonensis control in a mechanism dependent on IL-1R signaling by noncanonical NLRP3 inflammasome activation [14, 24]. In these settings, L. amazonensis elimination by P2X7R activation was followed by LTB4 release and subsequent activation of the NLRP3 complex and IL-1β release, requiring the activation of both CASP-1 and CASP-11 [4, 14]. NLRP3 activation by LTB4 depended on ROS induction [38]. Likewise, P2X7R activation triggered ROS production and the host immune response in several intracellular pathogen diseases, including Toxoplasma gondii, Chlamydia spp., and Plasmodium chabaudi infections [3941].

P2X7R was also necessary for antiparasitic responses attributed to UTP/P2YR in L. amazonensis infection [19]. The elimination of L. amazonensis in vitro triggered by P2Y2R involves P2X7-dependent LTB4 secretion, in a mechanism requiring pannexin-1. P2X7R expression was also required for in vivo control of L. amazonensis by UTP, supporting the notion of a collaborative effect among P2 receptors to improve the antiparasitic immune response in leishmaniasis [19]. In the present study, we showed, through in vitro and in vivo studies, that CASP-1 and IL-1R signaling, but not CASP-11, were necessary to boost host immune responses induced by P2Y2R, contributing to protection against L. amazonensis.

Antileishmanial effects triggered by P2Y2R involve two steps. The first one is mediated by ATP release with an autocrine/paracrine effect on P2X7R [19]. The second reveals a pathway of IL-1β induction triggered by P2Y2R (activated by low ATP concentrations). Corroborating our results, P2YR signaling triggered inflammasome activation in several inflammatory models [9, 13], and caspase-1-mediated secretion of IL-1β after activation of NLRP3 [9] and NLCR4 inflammasomes [42] after P2Y2R activation have been reported.

In the present study, we showed that P2Y2R induced lower levels of extracellular IL-1β when compared to P2X7R engagement by exogenous ATP, even though the technique used to measure extracellular nucleotides did not directly reflect their concentration around cells. These findings suggest that the P2X7R-dependent pathway triggered by P2Y2R could be activated to a lesser extent than that of P2X7R activation triggered by exogenous ATP. P2X7 receptor activation and its effect on immune cells vary according to ATP levels. P2X7 receptor stimulation with low ATP (100 μM) leads to the formation of a cation-selective channel. Its activation by high levels of ATP triggers the formation of a nonselective pore [43, 44]. The latter scenario is usually related to pronounced ROS production, inflammasome activation, and IL-1β release in various systems [45]. High ATP levels can activate the P2X7R that acts as the second signal for noncanonical NLRP3 inflammasome activation during L. amazonensis infection. Chaves et al. [14] demonstrated activation of the noncanonical NLRP3 and IL-1β release after P2X7R activation in vitro after incubation of infected macrophages with exogenous ATP (500 μM) [14]. In this context, P2X7R activation by high exogenous ATP concentrations during infection with L. amazonensis might lead to higher levels of extracellular LTB4, which in turn would favor ROS production and triggering of the noncanonical NLRP3 inflammasome assembly. Our data suggest that P2Y2 receptor activation is not able to induce P2X7 receptor activation at a level that triggers activation of the noncanonical NLRP3 inflammasome assembly. Nevertheless, the exact inflammasome-related pathways triggered under these conditions are unknown and require further studies.

Our in vivo results showed that, while lack of CASP-1/11 abrogated IL-1β induction and reduction in parasite load after activation of P2Y2R, mice deficient in CASP-11 preserved an antileishmanial response after treatment with UTP. These findings suggest that, during in vivo infection by L. amazonensis, caspase-1 is the main source of IL-1β and is responsible for controlling the parasitic infection. This pathway is further enhanced by P2Y2R signaling. Even though P2X7R activation appears to enhance IL-1β production through the noncanonical NLRP3 in vitro [14], its participation in the control of in vivo infection by L. amazonensis has not been addressed. It needs to be studied in depth before reaching further conclusions. Taken together, these data suggest that not only P2X7R but also P2Y2R, a G-protein-coupled receptor, is involved in the activation of IL-1β production/release in immune cells during infection with L. amazonensis. IL-1R activation, in turn, controls L. amazonensis infection. These results suggest that DAMPs boost the immune response against L. amazonensis infection via P2 receptors.

5. Conclusion

P2Y2R activation by UTP/ATP induced CASP-1 activation and IL-1β secretion in the context of L. amazonensis infection. IL-1β/IL-1R signaling was crucial to P2Y2R-mediated protective immune responses in an experimental model of cutaneous leishmaniasis. These findings suggest that P2Y2R may be a possible therapeutic target to treat L. amazonensis infection by potentiating IL-1β/IL-1R signaling and controlling parasite replication.

Data Availability

The file data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no competing or financial interests.


The authors wish to thank Pryscilla Braga, Fabiane Cristina Rodrigues, and Barbara Gabrielle Araujo for technical assistance. This work was supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundacão de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ, Brazil—E-26/010.002985/2014, E-26/203.027/2 015, E-26/202.774/2018, and E-26/202.701/2019).

Supplementary Materials

Supplementary Figure 1: infected peritoneal macrophages from BALB/c (A) were pretreated with Z-YVAD-FMK (2 μM) for 30 minutes and then with 100 μM UTP for another 30 minutes. Peritoneal macrophages from WT or CASP-11-/- were infected and after 48 h treated or not with UTP (100 μM) for 30 minutes (B). Twenty-four hours later, cells were fixed and stained with panoptic stain, and glass coverslips on slides were evaluated using the “infection index” by a direct count under light microscopy. Data represent of three independent experiments performed in triplicate, with pools of 3–4 animals in each experiment. relative to the untreated group (one-way analysis of variance followed by Tukey’s test). (Supplementary Materials)


  1. S. Burza, S. L. Croft, and M. Boelaert, “Leishmaniasis,” The Lancet, vol. 392, no. 10151, pp. 951–970, 2018. View at: Publisher Site | Google Scholar
  2. J. Alvar, I. D. Vélez, C. Bern et al., “Leishmaniasis worldwide and global estimates of its incidence,” PLoS One, vol. 7, no. 5, article e35671, 2012. View at: Publisher Site | Google Scholar
  3. D. Sacks and N. Noben-Trauth, “The immunology of susceptibility and resistance to Leishmania major in mice,” Nature Reviews. Immunology, vol. 2, no. 11, pp. 845–858, 2002. View at: Publisher Site | Google Scholar
  4. M. M. Chaves, C. Marques-da-Silva, A. P. Monteiro, C. Canetti, and R. Coutinho-Silva, “Leukotriene B4 modulates P2X7 receptor-mediated Leishmania amazonensis elimination in murine macrophages,” Journal of Immunology, vol. 192, no. 10, pp. 4765–4773, 2014. View at: Publisher Site | Google Scholar
  5. L. E. B. Savio and R. Coutinho-Silva, “Immunomodulatory effects of P2X7 receptor in intracellular parasite infections,” Current Opinion in Pharmacology, vol. 47, pp. 53–58, 2019. View at: Publisher Site | Google Scholar
  6. V. Ralevic and G. Burnstock, “Receptors for purines and pyrimidines,” Pharmacological Reviews, vol. 50, pp. 413–492, 1998. View at: Google Scholar
  7. K. A. Jacobson, E. G. Delicado, C. Gachet et al., “Update of P2Y receptor pharmacology: IUPHAR Review 27,” British Journal of Pharmacology, vol. 177, no. 11, pp. 2413–2433, 2020. View at: Publisher Site | Google Scholar
  8. D. Le Duc, A. Schulz, V. Lede et al., “P2Y receptors in immune response and inflammation,” in Advances in Immunology, pp. 85–121, Elsevier, 2017. View at: Publisher Site | Google Scholar
  9. L. Baron, A. Gombault, M. Fanny et al., “The NLRP3 inflammasome is activated by nanoparticles through ATP, ADP and adenosine,” Cell Death & Disease, vol. 6, p. 1629, 2015. View at: Google Scholar
  10. H. Jin, Y. S. Ko, and H. J. Kim, “P2Y2R-mediated inflammasome activation is involved in tumor progression in breast cancer cells and in radiotherapy-resistant breast cancer,” International Journal of Oncology, vol. 53, pp. 1953–1966, 2018. View at: Google Scholar
  11. G. S. Lee, N. Subramanian, A. I. Kim et al., “The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP,” Nature, vol. 492, no. 7427, pp. 123–127, 2012. View at: Publisher Site | Google Scholar
  12. M. Rossol, M. Pierer, N. Raulien et al., “Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors,” Nature Communications, vol. 3, no. 1, p. 1329, 2012. View at: Publisher Site | Google Scholar
  13. T. Suzuki, K. Kohyama, K. Moriyama et al., “Extracellular ADP augments microglial inflammasome and NF-kappa B activation via the P2Y12 receptor,” European Journal of Immunology, vol. 50, no. 2, pp. 205–219, 2019. View at: Google Scholar
  14. M. M. Chaves, D. A. Sinflorio, M. L. Thorstenberg et al., “Non-canonical NLRP3 inflammasome activation and IL-1β signaling are necessary to L. amazonensis control mediated by P2X7 receptor and leukotriene B4,” PLoS Pathogens, vol. 15, article e1007887, 2019. View at: Google Scholar
  15. D. S. Lima-Junior, D. L. Costa, V. Carregaro et al., “Inflammasome-derived IL-1β production induces nitric oxide-mediated resistance to Leishmania,” Nature Medicine, vol. 19, no. 7, pp. 909–915, 2013. View at: Publisher Site | Google Scholar
  16. P. Pelegrin and A. Surprenant, “Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor,” The EMBO Journal, vol. 25, no. 21, pp. 5071–5082, 2006. View at: Publisher Site | Google Scholar
  17. S. Ruhl and P. Broz, “Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux,” European Journal of Immunology, vol. 45, no. 10, pp. 2927–2936, 2015. View at: Publisher Site | Google Scholar
  18. D. Yang, Y. He, R. Munoz-Planillo, Q. Liu, and G. Nunez, “Caspase-11 requires the pannexin-1 channel and the purinergic P2X7 pore to mediate pyroptosis and endotoxic shock,” Immunity, vol. 43, no. 5, pp. 923–932, 2015. View at: Publisher Site | Google Scholar
  19. M. L. Thorstenberg, M. V. Rangel Ferreira, N. Amorim et al., “Purinergic cooperation between P2Y2 and P2X7 receptors promote cutaneous leishmaniasis control: involvement of pannexin-1 and leukotrienes,” Frontiers in Immunology, vol. 9, p. 1531, 2018. View at: Publisher Site | Google Scholar
  20. C. Marques-da-Silva, M. M. Chaves, S. P. Chaves et al., “Infection with Leishmania amazonensis upregulates purinergic receptor expression and induces host-cell susceptibility to UTP-mediated apoptosis,” Cellular Microbiology, vol. 13, no. 9, pp. 1410–1428, 2011. View at: Publisher Site | Google Scholar
  21. C. Marques-da-Silva, M. M. Chaves, M. L. Thorstenberg et al., “Intralesional uridine-5-triphosphate (UTP) treatment induced resistance to Leishmania amazonensis infection by boosting Th1 immune responses and reactive oxygen species production,” Purinergic Signal, vol. 14, no. 2, pp. 201–211, 2018. View at: Publisher Site | Google Scholar
  22. A. C. A. Moreira-Souza, C. L. C. Almeida-da-Silva, T. P. Rangel et al., “The P2X7 receptor mediates Toxoplasma gondii control in macrophages through canonical NLRP3 inflammasome activation and reactive oxygen species production,” Frontiers in Immunology, vol. 8, article 1257, 2017. View at: Publisher Site | Google Scholar
  23. R. G. Titus, M. Marchand, T. Boon, and J. A. Louis, “A limiting dilution assay for quantifying Leishmania major in tissues of infected mice,” Parasite Immunology, vol. 7, no. 5, pp. 545–555, 1985. View at: Publisher Site | Google Scholar
  24. M. M. Chaves, C. Canetti, and R. Coutinho-Silva, “Crosstalk between purinergic receptors and lipid mediators in leishmaniasis,” Parasites & Vectors, vol. 9, no. 1, p. 489, 2016. View at: Publisher Site | Google Scholar
  25. P. Scott and F. O. Novais, “Cutaneous leishmaniasis: immune responses in protection and pathogenesis,” Nature Reviews. Immunology, vol. 16, no. 9, pp. 581–592, 2016. View at: Publisher Site | Google Scholar
  26. S. P. Chaves, E. C. Torres-Santos, C. Marques et al., “Modulation of P2X7 purinergic receptor in macrophages by Leishmania amazonensis and its role in parasite elimination,” Microbes and Infection, vol. 11, no. 10-11, pp. 842–849, 2009. View at: Publisher Site | Google Scholar
  27. V. R. Figliuolo, S. P. Chaves, L. E. B. Savio et al., “The role of the P2X7 receptor in murine cutaneous leishmaniasis: aspects of inflammation and parasite control,” Purinergic Signal, vol. 13, no. 2, pp. 143–152, 2017. View at: Publisher Site | Google Scholar
  28. Y. Marinho, C. Marques-da-Silva, P. T. Santana et al., “MSU crystals induce sterile IL-1β secretion via P2X7 receptor activation and HMGB1 release,” Biochimica et Biophysica Acta (BBA) - General Subjects, vol. 1864, article 129461, 2020. View at: Publisher Site | Google Scholar
  29. L. E. B. Savio, M. P. de Andrade, C. G. da Silva, and R. Coutinho-Silva, “The P2X7 receptor in inflammatory diseases: angel or demon?” Frontiers in Pharmacology, vol. 9, p. 52, 2018. View at: Publisher Site | Google Scholar
  30. R. V. H. de Carvalho, W. A. Andrade, D. S. Lima-Junior et al., “Leishmania lipophosphoglycan triggers caspase-11 and the non-canonical activation of the NLRP3 inflammasome,” Cell Reports, vol. 26, no. 2, pp. 429–437.e5, 2019. View at: Publisher Site | Google Scholar
  31. D. S. Zamboni and D. S. Lima-Junior, “Inflammasomes in host response to protozoan parasites,” Immunological Reviews, vol. 265, no. 1, pp. 156–171, 2015. View at: Publisher Site | Google Scholar
  32. D. S. Zamboni and D. L. Sacks, “Inflammasomes and Leishmania: in good times or bad, in sickness or in health,” Current Opinion in Microbiology, vol. 52, pp. 70–76, 2019. View at: Publisher Site | Google Scholar
  33. R. V. H. de Carvalho, A. L. N. Silva, L. L. Santos, W. A. Andrade, K. S. G. de Sa, and D. S. Zamboni, “Macrophage priming is dispensable for NLRP3 inflammasome activation and restriction of Leishmania amazonensis replication,” Journal of Leukocyte Biology, vol. 106, no. 3, pp. 631–640, 2019. View at: Publisher Site | Google Scholar
  34. D. S. Lima-Junior, T. W. P. Mineo, V. L. G. Calich, and D. S. Zamboni, “Dectin-1 activation during Leishmania amazonensis phagocytosis prompts Syk-dependent reactive oxygen species production to trigger inflammasome assembly and restriction of parasite replication,” Journal of Immunology, vol. 199, no. 6, pp. 2055–2068, 2017. View at: Publisher Site | Google Scholar
  35. C. Pellegrini, L. Antonioli, G. Lopez-Castejon, C. Blandizzi, and M. Fornai, “Canonical and non-canonical activation of NLRP3 inflammasome at the crossroad between immune tolerance and intestinal inflammation,” Front Immunology, vol. 8, article 36, 2017. View at: Publisher Site | Google Scholar
  36. V. R. Figliuolo, S. P. Chaves, L. E. B. Savio et al., “Toll or interleukin-1 receptor (TIR) domain-containing adaptor inducing interferon-β (TRIF)-mediated caspase-11 protease production integrates toll-like receptor 4 (TLR4) protein- and Nlrp3 inflammasome-mediated host defense against enteropathogens,” The Journal of Biological Chemistry, vol. 287, no. 41, pp. 34474–34483, 2012. View at: Publisher Site | Google Scholar
  37. N. Kayagaki, M. T. Wong, I. B. Stowe et al., “Noncanonical inflammasome activation by intracellular LPS independent of TLR4,” Science, vol. 341, no. 6151, pp. 1246–1249, 2013. View at: Publisher Site | Google Scholar
  38. F. A. Amaral, V. V. Costa, L. D. Tavares et al., “NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B (4) in a murine model of gout,” Arthritis and Rheumatism, vol. 64, no. 2, pp. 474–484, 2012. View at: Publisher Site | Google Scholar
  39. G. Corrêa, C. M. da Silva, A. C. de Abreu Moreira-Souza, R. C. Vommaro, and R. Coutinho-Silva, “Activation of the P2X7 receptor triggers the elimination of Toxoplasma gondii tachyzoites from infected macrophages,” Microbes and Infection, vol. 12, no. 6, pp. 497–504, 2010. View at: Publisher Site | Google Scholar
  40. R. Coutinho-Silva, L. Stahl, M. N. Raymond et al., “Inhibition of chlamydial infectious activity due to P2X7R-dependent phospholipase D activation,” Immunity, vol. 19, no. 3, pp. 403–412, 2003. View at: Publisher Site | Google Scholar
  41. A. C. A. Moreira-Souza, Y. Marinho, G. Correa et al., “Pyrimidinergic receptor activation controls Toxoplasma gondii infection in macrophages,” PLoS One, vol. 10, no. 7, article e0133502, 2015. View at: Publisher Site | Google Scholar
  42. H. Jin and H. J. Kim, “NLRC4, ASC and caspase-1 are inflammasome components that are mediated by P2Y2R activation in breast cancer cells,” International Journal of Molecular Sciences, vol. 21, no. 9, p. 3337, 2020. View at: Publisher Site | Google Scholar
  43. R. Coutinho-Silva, L. A. Alves, W. Savino, and P. M. Persechini, “A cation non-selective channel induced by extracellular ATP in macrophages and phagocytic cells of the thymic reticulum,” Biochimica et Biophysica Acta, vol. 1278, no. 1, pp. 125–130, 1996. View at: Publisher Site | Google Scholar
  44. R. Coutinho-Silva and P. M. Persechini, “P2Z purinoceptor-associated pores induced by extracellular ATP in macrophages and J774 cells,” American Journal of Physiology, vol. 273, pp. C1793–C1800, 1997. View at: Google Scholar
  45. S. C. Hung, C. H. Choi, N. Said-Sadier et al., “P2X4 assembles with P2X7 and pannexin-1 in gingival epithelial cells and modulates ATP-induced reactive oxygen species production and inflammasome activation,” PLoS One, vol. 8, no. 7, article e70210, 2013. View at: Publisher Site | Google Scholar

Copyright © 2020 Maria Luiza Thorstenberg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.